Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Improved results with combined donor-specific transfusion (DST) and sequential therapy protocol.

O Salvatierra1, J McVicar, J Melzer

  • 1Transplant Service, University of California, San Francisco 94143-0116.

Transplantation Proceedings
|February 1, 1991
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 7 1506-1514, 2007.

Clinical journal of the American Society of Nephrology : CJASN·2023
Same author

Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: The CAESAR Study. Am J Transplant 7, 560-570, 2007.

Clinical journal of the American Society of Nephrology : CJASN·2023
Same author

dLLME-μSPE extraction coupled to HPLC-ESI-MS/MS for the determination of F2α-IsoPs in human urine.

Journal of pharmaceutical and biomedical analysis·2020
Same author

Phlebotomy resulting in controlled hypovolaemia to prevent blood loss in major hepatic resections (PRICE-1): a pilot randomized clinical trial for feasibility.

The British journal of surgery·2020
Same author

Mycophenolate Mofetil Withdrawal With Conversion to Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients.

Transplantation proceedings·2017
Same author

Ten-year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4-weekly or 8-weekly.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2017

A new combined DST-sequential Cyclosporine A (CyA) therapy protocol improves graft survival in living donor kidney transplants. This optimized protocol also reduces medication dosages and infection rates post-transplant.

Area of Science:

  • Immunology
  • Transplantation Medicine
  • Pharmacology

Background:

  • Optimizing graft survival in living donor kidney transplantation remains a critical challenge.
  • Minimizing immunosuppressive drug toxicity and infection risk is essential for long-term patient outcomes.

Purpose of the Study:

  • To evaluate a combined DST-sequential Cyclosporine A (CyA) therapy protocol for living related donor-recipient combinations with 1- and 2-haplotype mismatches.
  • To assess the impact of this protocol on graft survival, drug dosage, and infection rates.

Main Methods:

  • Implementation of a combined DST-sequential CyA therapy protocol.
  • Monitoring of graft survival over a 4-year period.
  • Assessment of prednisone and CyA dosage levels and infection rates post-transplantation.

Related Experiment Videos

Main Results:

  • Achieved optimum graft survival in 1- and 2-haplotype mismatched living related donor-recipient combinations.
  • Demonstrated excellent graft survival for up to 4 years.
  • Resulted in lower prednisone and CyA dosage levels.
  • Significantly decreased infection rates during the posttransplant period.

Conclusions:

  • The combined DST-sequential CyA therapy protocol offers superior graft survival in specific living donor kidney transplant scenarios.
  • This protocol allows for reduced immunosuppression, leading to fewer infections and improved patient safety.